Posted by Michael Wonder on 16 Apr 2019
Federal Government takes first major step in adopting new wave of personalised medicine for Australian patients
16 April 2019 - Medicines Australia welcomes the Government’s investment in new technology with Kymriah (tisagenlecleucel) CAR-T (Chimeric Antigen Receptor T-cell) therapy by Novartis being reimbursed for Australian children and young adults with acute lymphoblastic leukaemia (ALL).
Medicines Australia CEO Liz de Somer said immunotherapies, like CAR-T, represent a significant scientific development in the way diseases can be treated. CAR-Ts are living therapies and use a reengineered version of a person’s cell to treat cancer.
“Australians know these therapies exist and have previously had to travel overseas to access treatment. The therapy has been available in the US since 2017 and was approved in the UK and Canada in late 2018.
